תאריך רישום: October 22, 2009

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

H01BA02 :ATC Code

4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.

תאריך רישום: October 22, 2009

מסלול הגשה: מולקולה חדשה

יצרן: FERRING INTERNATIONAL CENTER SA, SWITZERLAND

בעל רישום: FERRING PHARMACEUTICALS LTD

H01BA02 :ATC Code

4.1 Therapeutic indications Minirin tablets are indicated for Central Diabetes Insipidus, Nocturnal Enuresis (in patients from 5 years of age with normal ability to concentrate the urine) and for symptomatic treatment of nocturia in adults associated with nocturnal polyuria, i.e. nocturnal urine production exceeding bladder capacity. The treatment must be started before the age of 65.

תאריך רישום: June 5, 2008

מסלול הגשה: מולקולה חדשה

יצרן: ANALYTISCHES ZENTRUM BIOPHARM GMBH BERLIN, GERMANY

בעל רישום: SANDOZ PHARMACEUTICALS ISRAEL LTD

L01XX17 :ATC Code

4.1 Therapeutic indications HYCAMTIN capsules are indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).

תאריך רישום: November 8, 2023

מסלול הגשה: מולקולה חדשה

יצרן: ANDERSONBRECON INC., USA

בעל רישום: J-C HEALTH CARE LTD

L01FX29 :ATC Code

4.1 Therapeutic indications TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

תאריך רישום: November 8, 2023

מסלול הגשה: מולקולה חדשה

יצרן: ANDERSONBRECON INC., USA

בעל רישום: J-C HEALTH CARE LTD

L01FX29 :ATC Code

4.1 Therapeutic indications TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

תאריך רישום: December 1, 2022

מסלול הגשה: מולקולה חדשה

יצרן: SANOFI PASTEUR INC., USA

בעל רישום: SANOFI ISRAEL LTD

J07AH02 :ATC Code